Recombinant DNA Technology Market, by Product Type (Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell and Gene Therapy and Gene Editing), by Application (Therapeutics, Agriculture, and Research), and by Region (Nort

Recombinant DNA Technology Market, by Product Type (Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell and Gene Therapy and Gene Editing), by Application (Therapeutics, Agriculture, and Research), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Recombinant DNA (rDNA) technology is a novel technique that has led to advances in a number of different fields such as drug development, agriculture, and research. Recombinant DNA technology has introduced new classes of organisms namely genetically modified organism (GMO) or living modified organism (LMO). It can develop genetically modified crops (BT cotton), cloned animals, bio pesticides, biofuel, and gene therapy successfully. rDNA technology has triggered the biopharmaceutical industries towards the development of various rDNA products such as CAR-T cell therapy and bispecific and monoclonal antibodies, in turn, favoring the growth of the recombinant DNA technology market. Moreover, the gene-editing system –Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) – holds great potential for the development of vaccines and drugs, as it plays a major role in the stability and enhancement of immunity.

Market Dynamics

The increasing adoption of inorganic strategies such as partnership is expected to drive the market growth over the forecast period. For instance, in September 2020, according to the data published by the National Center for Biotechnology Information, Serum Institute of India Pvt., Ltd. (SII), a biotechnology and Biopharmaceutical Company based in India, and the Indian Council of Medical Research (ICMR), an autonomous organization under the Department of Health Research, partnered for the clinical development of two global vaccine candidates. The first one is ChAdOx1-S, which is a non-replicating viral vector vaccine developed by the University of Oxford/AstraZeneca. This vaccine is undergoing phase III clinical trials in Brazil. Phase II/III bridging studies have been initiated by ICMR at 14 clinical trial sites. ICMR-National Institute for Research in Tuberculosis (NIRT), Chennai is the lead institution.

Moreover, in September 2020, ICMR and Serum Institute of India Pvt., Ltd. (SII) have also partnered for the clinical development of a glycoprotein subunit nanoparticle adjuvanted vaccine, developed by Novavax, Inc., biotechnology company that develops vaccines to counter serious infectious diseases from the U.S. The trial will be initiated in the second half of October 2020 after the vaccine is manufactured by SII. The trial is led by ICMR-National AIDS Research Institute (NARI), Pune, India.

Key features of the study:

• This report provides an in-depth analysis of the global recombinant DNA technology market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global recombinant DNA technology market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global recombinant DNA technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant DNA technology market

Detailed Segmentation:

• Global Recombinant DNA Technology Market, By Product Type:
• Recombinant Protein Drugs
• Insulin
• Human Growth Hormone
• Erythropoietin
• Interferon
• Blood Factors
• Colony Stimulating Factors
• Fusion Proteins
• Others
• Vaccines
• Genetically Modified Crops
• Expression Systems
• Prokaryotic Cells
• Mammalian Cells
• Yeats
• Insect
• Others
• Cell and Gene Therapy
• Gene Editing
• Global Recombinant DNA Technology Market, By Application:
• Therapeutics
• Agriculture
• Research
• Global Recombinant DNA Technology Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Thermo Fisher Scientific, Inc.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Biogen, Inc.
• Sanofi Pasteur
• Merck & Co., Inc.
• Pfizer, Inc.
• Profacgen
• Amgen, Inc.
• Monsanto Company

“*” marked represents similar segmentation in other categories in the respective section.